CWBR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 18:25):

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases...

Stats
Šios dienos apimtis	1 605.00
Vidutinė apimtis	1 898.00
Rinkos kapitalizacija	2.33M
EPS	$0 ( 2024-05-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.180
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-01	Biunno Jeffrey Francis	Buy	26 203	Common Stock
2022-08-01	Sarret Joseph J.	Buy	131 017	Common Stock
2022-07-11	Tozzo Stephanie	Buy	200 000	Stock Option (Right to buy)
2022-07-11	Tozzo Stephanie	Buy	0
2021-12-29	Biunno Jeffrey Francis	Buy	75 000	Stock Option (Right to buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 7 451 858 \| Sell: 253 700

CohBar Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
YJ	0.911
EFOI	0.867
PRVB	0.865
SMED	0.863
CXSE	0.859
PXLW	0.857
HLBZ	0.856
PCTTU	0.849
MCHI	0.848
WB	0.839

10 Labiausiai neigiamai susiję koreliacijos
HZNP	-0.876
PPBT	-0.834
SLGG	-0.829
LEDS	-0.81

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

CohBar Inc Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-4.13

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-4.13

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-9.51

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-10.00

Financial Reports:

No articles found.

CohBar Inc

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.